Immunofoco HKEX IPO filing lapses; core CAR-T therapy IMC002 enters pivotal Phase III

NewTimeSpace News: Shenzhen Immunofoco Biotechnology Co., Ltd. submitted its listing application to HKEX on 13 February 2026, which has lapsed after six months. Huatai International acted as the original sole sponsor.

Founded in 2020, the Company is a global leading innovative cell therapy company. Its core product IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, ranks second globally in clinical progress and is currently in the pivotal Phase III stage. The Company also holds IMC001, a potentially first-in-class anti-EpCAM CAR-T cell therapy candidate in clinical stage (Phase I/IIa), and an exclusive ex vivo CAR-T proprietary manufacturing process with significant cost advantages.

The Company has built a dual-engine growth model encompassing both ex vivo and in vivo CAR-T cell therapy, developing off-the-shelf products through its differentiated iMAGIC in vivo CAR-T platform to expand potential therapeutic areas. According to Frost & Sullivan, the global CAR-T cell therapy market is expected to grow from USD 4.7 billion in 2024 to USD 35.2 billion in 2035, representing a compound annual growth rate of 20.2%; the China market is expected to grow from RMB 1.0 billion in 2024 to RMB 50.7 billion in 2035.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.